Azathioprine was administered via drinking water (6-20 mg/kg body weight per day) to mice that were null (Msh2 , and 12 Msh2 WT ) received drinking water lacking azathioprine. The effect of azathioprine on tumorigenesis and survival of the mice was evaluated by Kaplan-Meier curves using log-rank and Gehan-Breslow-Wilcoxon tests. Mouse tumor samples were characterized by histology and immunophenotyping, and their MSI status was determined by polymerase chain reaction analysis of three noncoding microsatellite markers and by immunohistochemistry. Msh2 status of tumor samples was assessed by loss of heterozygosity analyses and sequencing after reverse transcription-polymerase chain reaction of the entire Msh2 coding sequence. All statistical tests were two-sided.
Numerous studies have reported an increased risk of cancer among patients who received long-term therapy with drugs, including alkylating agents, topoisomerase inhibitors, and antimetabolites. Because of substantial improvements in drug therapy treatments, patients are now surviving longer and the number of iatrogenic cancers they develop has steadily increased. These cancers likely reflect not only late effects of therapy but also the individual patient's genetic susceptibility, given that individual polymorphic variation in genes involved in carcinogen metabolism and detoxification and DNA repair pathways have been associated with the risk of developing iatrogenic cancers (1) . It is therefore important to identify the oncogenic mechanisms responsible for the development of therapy-related malignancies and to understand genetic susceptibility factors that may allow for the identification of individuals at risk for such malignancies.
Among the frequently prescribed antimetabolites are the thiopurines, which comprise azathioprine, 6-mercaptopurine, and 6-thioguanine. Originally used in clinical practice to treat childhood acute lymphoblastic leukemia, 6-mercaptopurine therapy has markedly improved the prognosis of patients with this malignancy (2) . The introduction of azathioprine in the 1960s as an immunosuppressant following organ transplantation has also contributed to ARTICLE Azathioprine-Induced Carcinogenesis in Mice According to Msh2 Genotype
Background
The thiopurine prodrug azathioprine is used extensively in cancer therapy. Exposure to this drug results in the selection of DNA mismatch repair-deficient cell clones in vitro. It has also been suggested that thiopurine drugs might constitute a risk factor for the emergence of human neoplasms displaying microsatellite instability (MSI) because of deficient DNA mismatch repair.
improvements in patient survival (3) . Both drugs are also effective against autoimmune disorders, such as rheumatoid arthritis, autoimmune dermatological diseases, and inflammatory bowel diseases. Although it is now well established that prolonged treatment with thiopurine agents increases the risk of various cancer types, including non-Hodgkin lymphoma, cutaneous squamous cell carcinoma, hepatobiliary carcinoma, and mesenchymal tumors (4, 5) , the mechanism by which thiopurines contribute to carcinogenesis is not yet understood (6) . To date, much of the increased risks of secondary cancers due to thiopurines and other immunosuppressants have been attributed to the effects of immunosuppression per se and to the subsequent involvement of oncogenic viruses (7) . In vitro studies have also suggested that defects in the DNA mismatch repair system may be involved in thiopurine sensitivity because exposure of different cell lines to thiopurine agents consistently selects for cells with DNA mismatch repair defects (8) (9) (10) (11) . DNA mismatch repair is a system for recognizing and repairing the erroneous insertion, deletion, and misincorporation of bases that can arise during DNA replication and recombination, as well as for processing some forms of DNA damage. In eukaryotes, the main protein components of this system are Msh2 and Mlh1. All three thiopurines are inactive prodrugs that are metabolized through a multistep pathway to generate 6-thiodeoxyguanosine, which becomes incorporated into DNA, causing the misincorporation of thymine during DNA synthesis. Recognition and processing of the subsequent mispaired bases by the DNA mismatch repair system results in cell death (12, 13) . DNA mismatch repair-deficient cells are tolerant to thiopurines because they do not initiate lethal processing of the mispaired bases (14, 15) . Although DNA mismatch repair deficiency does not by itself cause cells to undergo malignant transformation, it is associated with an increased risk of cancers that exhibit a particular phenotype referred to as microsatellite instability (MSI), which is defined as alterations in the length of short repeated (usually mono-or dinucleotide) sequences of DNA (ie, microsatellites) in tumor tissue relative to normal tissue (16) (17) (18) .
The accumulation of somatic frameshift mutations defines a so-called mutator pathway that is likely to be oncogenic when it occurs in repeated sequences located within the coding sequence of genes involved in various biological pathways, such as the regulation of cell cycle and/or cell proliferation ( (19) . A high frequency of DNA mismatch repair deficiency has been reported in cancers that arise secondary to chemotherapy, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes, in which the incidence of DNA mismatch repair deficiency is approximately 50%, whereas in de novo AML, it is less than 5% (20) . Recent epidemiological studies have reported an association between DNA mismatch repair inactivation and the use of thiopurine regimens in AML and myelodysplastic syndromes that develop in patients treated for autoimmune disorders (5) and in AML and non-Hodgkin lymphomas that develop after organ transplantation (9, 21, 22) . In other clinical contexts such as inflammatory bowel disease, there is no evidence that thiopurines contribute to the development of intestinal neoplasias with MSI (23). To date, there has been no formal in vivo demonstration that these drugs have an effect on MSI-driven oncogenesis.
In this study, we used a mouse model to examine the possible causal association between DNA mismatch repair and thiopurine sensitivity. Azathioprine was administered to mice that were null (Msh2 
Materials and Methods

Mice and Treatment
Mismatch repair-deficient mice carrying a targeted disruption in exon 12 of the Msh2 gene were described previously (24) . Msh2 ϩ/Ϫ mice (129/Ola/FVB) (provided by Professor Hein te Riele) were intercrossed to obtain mice that were null, heterozygous, or wild type for the Msh2 gene. The genotypes of the mice were determined by using polymerase chain reaction (PCR) analysis, as previously described (25) . Groups of mice aged 6 weeks (27 Msh2 Ϫ/Ϫ mice, 22 Msh2 ϩ/Ϫ mice, and 18 Msh2 WT mice) received azathioprine (Imurel 50 mg; GlaxoSmithKline, Marly-le-Roi, France) orally via their drinking water; the estimated dose was 6-20 mg/kg body weight per day, given that a mouse weighs approximately 20-30 g and
CONTEXT AND CAVEATS
Prior knowledge
The thiopurine prodrug azathioprine is used extensively in cancer therapy and as an immunosuppressant in various clinical contexts. However, because exposure to azathioprine results in the selection of DNA mismatch repair-deficient cell clones in vitro, it may constitute a risk factor for the emergence of human neoplasms displaying microsatellite instability.
Study design
Azathioprine was administered to mice that were null (Msh2
), or wild type (Msh2 WT ) for the DNA mismatch repair gene Msh2 to examine the possible causal association between DNA mismatch repair and thiopurine sensitivity. The effect of azathioprine on tumorigenesis and survival of the mice was compared with that in untreated control mice.
Contribution
Azathioprine-induced carcinogenesis in mice depends on the number of functional copies of the Msh2 gene.
Implications
Exposure to azathioprine may be an important risk factor for the development of tumors with microsatellite instability, especially for individuals who carry mutations in DNA mismatch repair genes.
Limitations
Whether these observations can be extended to other frequently prescribed immunosuppressants whose actions are independent of DNA mismatch repair is not known.
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drinks approximately 4-8 mL of water per day. This dosage of azathioprine corresponds to a human dose equivalent of 0.5-1.6 mg/kg body weight per day (26) , which lies within the range of doses usually prescribed in human therapy (27) (28) (29) (30) (31) 
Histopathological and Immunohistochemical Studies
Mice that displayed signs of poor health including breath insufficiency and posterior leg paralysis were killed by cervical dislocation and autopsied. At autopsy, the spleen, liver, and thymus were systematically removed together with other enlarged organs or lymph nodes, and a portion of each type of tissue was stored at −80°C. The remaining portions of tissue were formalin fixed, embedded in paraffin, and sectioned for histological analysis and immunohistochemical staining for Mlh1 and Msh2. For histology, 4-µm sections were stained with hematoxylin-eosin. For Msh2 and Mlh1 immunohistochemistry, 4-µm sections were incubated with mouse monoclonal antibodies against MLH1 (mouse and human cross-reactive clone G168-728; 1:25 dilution; BD Pharmingen, San Diego, CA) and MSH2 (mouse and human cross-reactive clone FE11; 1:25 dilution; Calbiochem, Cambridge, MA) as previously described (32), followed by incubation with the appropriate secondary antibodies (Trekkie biotinylated mouse link and trekavidin-HRP label; Biocare, Paris, France). Stromal and normal lymphocytes that were present in the section served as the control for positive staining. For immunophenotyping, 6-µm thick acetone-fixed frozen sections of spleen were incubated with a rat monoclonal antibody against mouse CD45, which recognizes hematopoietic cells (clone 30-F11; 1:50 dilution; BD Pharmingen), a rabbit monoclonal antibody against CD3, which recognizes T cells (mouse and human cross-reactive clone sp7; 1:100 dilution; Interchim, Montluçon, France), and a biotinylated rat monoclonal antibody against mouse CD19, which recognizes B cells (clone 6D5; 1:100 dilution; Abcam, Paris, France). Sections were then incubated with the following horseradish peroxidase-conjugated secondary antibodies: rabbit anti-rat immunoglobulin G (1:250 dilution; Abcam), amplification system anti-rabbit (Ready-to-use Envision+ system; Dako, Trappes, France), and horseradish peroxidase-streptavidin conjugate (1:500 dilution; Zymed, Invitrogen, Cergy Pontoise, France), respectively. Peroxidase activity (ie, bound antibody) was detected with the use of a DAB+ kit (Dako).
Microdissection of Mouse Tumor Tissue Sections
The tumor cell component from two azathioprine-treated Msh2 WT mice selected at random was collected from 10 hematoxylin-and eosin-stained 7-µm tissue sections per mouse with the use of a laser-capture microdissection system (PALM Laser; Zeiss, Le Pecq, France) and used for DNA extraction.
PCR-Based Msh2
Genotyping of Normal and Tumor DNA Normal DNA (from mouse tail) and tumor DNA were extracted with the use of a QIAamp DNA extraction kit (Qiagen, Courtaboeuf, France) according to the manufacturer's instructions. Msh2 genotype analysis was performed as previously described (25) by using a three-primer allele-specific PCR assay in which the wild-type and inactivated Msh2 alleles generated PCR products of 164 and 194 bp, respectively. Briefly, PCR was performed using Taq DNA Polymerase kit (Qiagen) with 0.5 mM MgCl 2 , 0.2 mM dNTP mix, and 0.5pmol/µL of each primer (primers are detailed in Supplementary Table 1, available online). PCR conditions were 94°C for 5 minutes followed by 35 cycles of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds, and a final extension at 72°C for 7 minutes. The PCR products were resolved on agarose gels. To assess loss of heterozygosity of the Msh2 allele, quantitative densitometry scanning of the DNA bands on a 4% agarose gel was carried out with the use of GeneTools software (version 4.01; Syngene, Saint Quentin en Yvelines, France). Allelic loss was calculated using the following normalized allelic imbalance ratio (WT tumor to D tumor)/(WT normal to D normal), where WT and D correspond to the wild-type and disrupted alleles, respectively. An allelic imbalance ratio less than 0.6 was considered indicative of loss of heterozygosity based on the observation that some tumors contained an estimated 40% of normal stromal cells interspersed among the tumor cells.
Msh2 Gene Sequencing
Reverse transcription-PCR was used to generate eight overlapping DNA fragments that covered the entire Msh2 coding sequence. Total RNA was extracted from nine mouse tissue samples four tumor sites and the corresponding normal tissue from mouse 36 (an azathioprine-treated Msh2 ϩ/Ϫ mouse that did not show loss of heterozygosity of the Msh2 allele), and tumor tissues from four other mice for controls (three azathioprine-treated Msh2 ϩ/Ϫ mice and one untreated Msh2 Ϫ/Ϫ mouse) with the use of an RNeasy extraction kit (Qiagen) according to the manufacturer's instructions. For reverse transcription, we used 700 µg of RNA and murine leukemia virus reverse transcriptase and oligo dT from a GeneAmp RNA PCR kit (Perkin Elmer, Courtaboeuf, France). PCR was performed with the use of a HotStarTaq DNA Polymerase kit (Qiagen) with 3 mM MgCl 2 and 0.3 µM of each primer (primers are detailed in Supplementary Table 1, available online). The PCR profile was 95°C for 15 minutes followed by 35 cycles of 95°C for 30 seconds, 63°C for 30 seconds, and 72°C for 1 minute. Sequencing was done by a linear amplification with the use of a Big Dye Terminator v1.1 Cycle sequencing kit (Applera, Courtaboeuf, France) according to the manufacturer's instructions. PCR products were analyzed on an ABI PRISM 3100 Genetic Analyzer (Applera). Identified DNA sequence variants were confirmed by sequencing both DNA strands.
Analysis of MSI
We used three noncoding mononucleotide repeats (all on chromosome 1) to determine tumor MSI status: A22, A24, and T40. PCR reactions were performed using DNA (50 ng) isolated from tumor and normal tissues from the same mouse, GoTaq DNA Polymerase (Promega, Charbonnieres, France), 1. seconds and 72°C for 30 seconds, with final extension at 72°C for 7 minutes. Amplified products were resolved on denaturing gels run in an ABI PRISM 3100 Genetic Analyzer and analyzed using Genescan 3.7 and Genotyper 2.1 software programs (Applera). We compared the predominant allele size observed in the tumor with that observed in normal tissue from the same mouse (ie, 190, 70, and 122 for markers A22, A24, and T40, respectively). Tumors were scored as MSI positive if the length of at least one marker in tumor DNA differed from that in normal tissue DNA.
Mutation Analysis of Target Genes for MSI
To confirm the role of MSI as an active oncogenic process in lymphoma cells, we screened for frameshift mutations in coding microsatellites of cancer-related genes. Most coding microsatellite sequences that are contained within human genes are not conserved in the murine genome. We therefore constructed an in silico database by querying GenBank (October 2007) for murine genes that contain coding microsatellite sequences greater than seven nucleotides in length (available on request from the authors). From this database, we selected nine genes with involvement in tumorigenesis that were possible targets for mutation by MSI: Sdccag1, Casc3, Kit, Casc5, Rasal2, FasL, Tcf7l2, Apc, and Akt3. Only one of these genes, Tcf7l2 (also known as Tcf-4, the main effector of Wnt and Wingless signaling), was known to be mutated in a conserved microsatellite sequence in human colorectal tumors with MSI (33) . Screening for mutation was performed by PCR using tumor or corresponding normal DNA (50 ng), primers specific for each gene (at 0.3 µM; Supplementary Table 1, available  online) , and a Taq DNA Polymerase kit (Qiagen). The PCR profile was 94°C for 4 minutes, followed by 35 cycles of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute, with a final extension at 72°C for 7 minutes. Tumors were scored as mutated if the length of the predominant allele in tumor DNA differed from that in normal tissue DNA.
Generation of Kaplan-Meier Survival Curves and Statistical Analysis
The health of the mice was examined daily. Mice that presented with signs of poor health were killed by cervical dislocation according to the recommendations of our Ethical Committee. In our experience, these signs are due to lymphomagenesis (34, 35) and precede the time of death by a couple of days. The time of death was recorded for each mouse that was found dead or had been killed. KaplanMeier survival curves were generated with the use of Graphpad Prism software (version 4; Graphpad, Inc, San Diego, CA). Comparisons of median survivals were performed using log-rank and Gehan-Breslow-Wilcoxon tests. Comparisons of the mean number of tumors in Msh2 Ϫ/Ϫ and treated Msh2 ϩ/Ϫ mice were performed using the Student t test. All statistical tests were two-sided.
Results
Effect of Azathioprine on Mouse Tumorigenesis and Survival According to Msh2 Genotype Previous studies demonstrated that heterozygous Msh2
ϩ/Ϫ mice have a normal lifespan, whereas most Msh2 Ϫ/Ϫ mice spontaneously develop diffuse aggressive lymphomas and succumb to these by 6-8 months of age (34, 35) . In agreement with these findings, we observed that most (82%) of the untreated Msh2 ϩ/Ϫ mice remained free of disease, whereas all untreated Msh2 Ϫ/Ϫ mice were dead by age 200 days (Figure 1) . Msh2 ϩ/Ϫ and Msh2 WT mice that received azathioprine via their drinking water showed statistically significantly shorter survival compared with the respective untreated mice: All treated mice were dead by age 250 days (log-rank test: P < .001; Gehan-Breslow-Wilcoxon test: P < .001). However, azathioprine-treated Msh2 ϩ/Ϫ mice had statistically significantly longer median survival compared with azathioprine-treated Msh2 WT mice (165 vs 71 days, difference = 94 days, 95% confidence interval [CI] = 55 to 133 days; P < .001 [Gehan-Breslow-Wilcoxon test]; Figure  1 ). Conversely, azathioprine-treated Msh2 Ϫ/Ϫ mice had slightly longer median survival compared with untreated Msh2 Ϫ/Ϫ mice (127 vs 107 days, difference = 20 days, 95% CI = −9 to 49 days, P = .03 log-rank test; P = .01 [Gehan-Breslow-Wilcoxon test]; Figure 1 ).
All azathioprine-treated Msh2 Ϫ/Ϫ mice (n = 15), untreated Msh2 Ϫ/Ϫ mice (n = 10), and azathioprine-treated Msh2 ϩ/Ϫ mice (n = 8) that were autopsied were found to have developed a tumoral phenotype that was characterized by abnormal enlargement of the thymus, spleen, and liver, sometimes in association with adenomegaly. Histological examination of all tumor masses revealed massive infiltration of organs by medium-to-large lymphoid cells (Figure 2 , A and Supplementary WT mice that were analyzed displayed obvious enlargement of organs; however, histological examination of these mice confirmed, in most instances (nine of 11 mice), the presence of microscopic foci comprising medium-to-large neoplastic lymphoid cells that were restricted to the spleen area located under the capsule (Figure 2, A) . There were no histological or immunophenotypical differences between azathioprine-induced and spontaneous lymphomas in mice with any Msh2 genotype (Figure 2 , B and Supplementary Table 3 [available online]). All but one of the lymphomas was of B-cell origin (ie, CD45 positive, CD19 positive, and CD3 negative); one tumor sample from an azathioprine-treated Msh2 ϩ/Ϫ mouse was of T-cell origin (ie, CD45 positive, CD19 negative, and CD3 positive).
MSI Status of Azathioprine-Induced Lymphomas in
Msh2
ϩ/Ϫ and Msh2 WT Mice We next examined tumor DNA for three noncoding microsatellite markers to determine whether the tumors that developed in azathioprine-treated Msh2 ϩ/Ϫ and Msh2 WT mice differed in terms of MSI status. Most of tumor DNA samples from Msh2 Ϫ/Ϫ mice displayed MSI (defined as a change in the length of one or more microsatellite loci compared with normal tissue DNA from the same mouse) (Figure 3, A) . In all, 43 of 50 lymphomas from 25 Msh2 Ϫ/Ϫ mice (including 15 of 18 lymphomas from 10 untreated mice and 28 of 32 lymphomas from 15 azathioprine-treated mice) displayed MSI demonstrating a sensitivity of 86% (95% CI = 73% ϩ/Ϫ mice did not exhibit change in the length of microsatellite loci, and alterations in the allelic size of the three markers were only occasionally observed in normal DNA from Msh2 ϩ/Ϫ mouse that was treated with azathioprine, we identified a variant form of Msh2 that contained a G to T transversion at codon 2074 in exon 13, which resulted in the substitution of glycine to tryptophan at amino acid 692 (Figure 4, B) . This mutation was present in the DNA from the four primary tumor sites in this mouse but absent from the normal DNA. Although this missense mutation has not been previously reported in HNPCC patients, it is important to note that it occurs in a well-conserved region of the gene and that the substitution of glycine to tryptophan at amino acid 692 has been reported in a Portuguese HNPCC family (36) , which suggest the possible pathogenicity of this variant. Moreover, an in silico analysis of the function of the mutated protein (performed on the PolyPhen: prediction of functional effects of human nsSNP website; http://g enetics.bwh.harvard.edu/pph/) predicted that the mutation was likely to disrupt the function of the Msh2 protein (data not shown).
By contrast, immunohistochemical analysis revealed that tumor samples from the nine azathioprine-treated Msh2 WT mice that displayed microscopic foci of neoplastic lymphoid cells retained the expression of the two DNA mismatch repair genes, Msh2 (Figure 3 , B and Supplementary Table 2 [available online]) and Mlh1 (data not shown), indicating that the carcinogenic process in these mice was unlikely to be due to inactivation of DNA mismatch repair.
Oncogenic Pathway in Lymphoma Cells with MSI from Control and Azathioprine-Treated Mice
Finally, to confirm the role of MSI as an active oncogenic process in lymphoma cells from mice in this study, we investigated whether the instability observed in noncoding microsatellites of DNA mismatch repair-deficient lymphoma cells was accompanied by somatic mutations in the coding microsatellites of cancer-related genes, as was previously reported (37) . We screened for frameshift mutations in coding microsatellites in nine candidate genes (Sdccag1, Casc3, Kit, Casc5, Rasal2, FasL, Tcf7l2, Apc, and Akt3) with putative roles in carcinogenesis. Screening for mutation was performed by Ϫ/Ϫ mice, and four untreated Msh2 Ϫ/Ϫ mice) (Figure 3, C) . Frameshift mutations were found in eight of the target genes, of which the Sdccag1 (serologically defined colon cancer antigen 1) and Casc3 (cancer susceptibility candidate 3) genes were mutated at relatively high frequencies in these tumors (58% and 21%, respectively; Figure 3 , C). The mutation frequency for each of the nine target genes was similar in spontaneous and azathioprine-induced lymphomas (data not shown). The relatively high frequencies of frameshift mutations in Sdccag1 and Casc3 pointed to an active oncogenic MSI pathway in lymphomas from Msh2 Ϫ/Ϫ and Msh2 ϩ/Ϫ mice. The human SDCCAG1 homolog has been identified as a tumor suppressor in non-small cell lung cancer cell lines (38, 39) . The Casc3 protein is a component of a splicing-dependent multi-protein junction complex that marks the position of the exon-exon junction in mature mRNA (40) , thereby influencing downstream gene expression processes including mRNA splicing, nuclear mRNA export, subcellular mRNA localization, translation efficiency, and nonsense-mediated mRNA decay. Casc3 could then play a role in MSI-driven carcinogenesis, given that numerous frameshift mutation-derived mRNAs are processed by the nonsense-mediated mRNA decay machinery in MSI tumors (41, 42) . It is noteworthy that in a given mouse, some tumor locations displayed a mutation in Sdccag1 or Casc3 genes, whereas other tumor sites did not, suggesting that the mutations occurred as independent molecular events during disease progression (Figure 3, D) .
Discussion
Thiopurines are effective anticancer agents and immunosuppressants in a variety of clinical conditions. However, they have been reported to be associated with an increased incidence of secondary tumors (6) . It is therefore important to identify the oncogenic mechanisms responsible for the development of iatrogenic neoplasms because such information could allow the identification of patients who may be at risk of developing tumors when treated with these drugs. For this purpose, we investigated whether a murine model could be used to examine the causal involvement of DNA mismatch repair in thiopurine sensitivity. We administered azathioprine to mice that were wild type or inactivated in one or both copies of the DNA mismatch repair gene Msh2. The dosage of azathioprine used in our mouse model corresponds to a human dose equivalent of 0.5-1.6 mg/kg body weight per day (26) and lies within the range usually prescribed in human therapy. As a mutagen and immunosuppressant, azathioprine was expected to induce tumor formation in mice, which turned out to be the case. However, it is interesting that we also found that the oncogenic pathway, the survival, and the tumoral phenotype of azathioprinetreated mice were influenced by their Msh2 status. Briefly, we observed that azathioprine-treated Msh2
WT and Msh2 ϩ/Ϫ mice developed lymphomas and died prematurely (median survival of 71 vs 165 days of age, respectively) compared with the respective untreated mice that mostly were alive at 250 days of age. However, we demonstrated that Msh2 ϩ/Ϫ mice developed diffuse lymphomas that lacked Msh2 expression and displayed MSI at both noncoding and coding microsatellite sequences because of somatic inactivation of the remaining functional Msh2 allele in tumor cells. By contrast, Msh2
WT mice presented with splenic microscopic foci of neoplastic lymphoid cells that retained both Msh2 and Mlh1 expression and did not display MSI. Both untreated and azathioprine-treated Msh2 Ϫ/Ϫ mice developed diffuse MSI lymphomas as expected, but surprisingly, the former had slightly longer median survival (median survival of 127 vs 107 days of age, respectively).
Our data thus clearly demonstrate the ability of azathioprine to trigger carcinogenesis through an MSI-driven process in vivo. To date, two mechanisms have been reported to underlie the cytotoxicity of azathioprine. First, azathioprine-induced purine starvation slows the rate of cell division, especially in lymphocytes, which, unlike other cell types, cannot use the salvage pathway of purine synthesis (43) (44) (45) . Importantly, this effect has not been demonstrated to be dependent on Msh2 status. Second, DNA mismatch repair-dependent signaling of azathioprine-induced DNA damage results in apoptosis in DNA mismatch repair-proficient cells (12, 13) . By contrast, DNA mismatch repair-deficient cells display thiopurine tolerance and are therefore able to escape cell death when exposed to azathioprine (14, 15) and subsequently undergo neoplastic cell transformation through the accumulation of genetic mutations caused by MSI. Moreover, the MSI-driven oncogenic pathway has been shown previously to favor the emergence of a tumor phenotype in mice that is characterized by an enlarged thymus, spleen, and liver and which leads Msh2 Ϫ/Ϫ mice to die from diffuse aggressive lymphomas (34, 35) . Taking all these elements into consideration, we propose the following explanations to account for the various oncogenic pathways, survival, and tumoral phenotypes observed in azathioprine-treated mice with different Msh2 status. First, untreated Msh2 Ϫ/Ϫ mice exhibited the characteristic development of MSI lymphomas, which were ultimately responsible for their death (see above). Azathioprinetreated Msh2 Ϫ/Ϫ mice displayed the same tumor phenotype as untreated mice, but had slightly longer survival, which may reflect reduced Msh2 Ϫ/Ϫ lymphocyte proliferation due to purine starvation resulting from azathioprine treatment. Second, azathioprinetreated Msh2 ϩ/Ϫ mice were similar to both treated and untreated Msh2 Ϫ/Ϫ mice with respect to tumor phenotype, histology, and MSI status of lymphoma cells. A reasonable explanation for this finding is that like (treated and untreated) Msh2 Ϫ/Ϫ mice, azathioprinetreated Msh2 ϩ/Ϫ mice died from lymphomas that had MSI and an active oncogenic mutator pathway. The longer median survival of azathioprine-treated Msh2 ϩ/Ϫ mice compared with azathioprinetreated Msh2 Ϫ/Ϫ mice (165 vs 127 days) may be due to the time required for somatic inactivation of the remaining functional Msh2 allele in the Msh2 ϩ/Ϫ mice, in accordance with the Knudson two-hit model (46) . Finally, azathioprine-treated Msh2 WT mice exhibited a distinct tumor phenotype but no enlarged organs. Histological examination revealed microscopic foci of lymphoma cells expressing Msh2 and Mlh1 under the splenic capsule, and careful examination of genomic DNA extracted from laser-capture microdissected tumor tissue excluded the presence of an MSI phenotype. Strikingly, these mice exhibited the shortest median survival. We speculate that these mice may have died from lymphomas that arose from oncogenic mechanisms other than MSI, such as chromosomal instability. Alternatively, these mice may have died from general organ failure due to the greater cytotoxicity of azathioprine in Msh2 WT cells. In support of the latter mechanism are data showing that human Msh2 ϩ/Ϫ lymphoblastoid cells are approximately fourfold more tolerant than wild-type cells to killing by temozolomide, a methylating agent known to involve a DNA mismatch repairdependent signaling response to DNA damage (47) .
Our findings could have important clinical implications for patients receiving azathioprine therapy. Msh2 Ϫ/Ϫ mice spontaneously develop lymphomas and display the phenotype of the rare patients with homozygous or biallelic inactivation of DNA mismatch repair genes, including a severely reduced lifespan and increased frequency of hematological malignancies compared with general population (48) . We have shown that all azathioprineinduced lymphomas in Msh2 ϩ/Ϫ mice arise from an MSI-driven oncogenic process following inactivation of the Msh2 wild-type allele, mainly through loss of heterozygosity. Mice with one constitutively inactivated Msh2 allele are the murine equivalent of ϩ/Ϫ mice (numbers correspond to mouse number). Some tumor sites showed complete loss of signal for the wild-type allele, whereas other sites showed residual signal corresponding to contamination from non-tumor cell DNA. The intensity ratio of the two allelic bands (wild type and disrupted) in tumor DNA relative to that obtained in normal (control) DNA was calculated and a ratio of 0.6 or less corresponding to a reduction of intensity of at least 40% in tumor DNA was used to score loss of heterozygosity. A) Loss of the wild-type Msh2 allele in all tumor sites for eight mice. LN = lymph node. B) Mutation of the wild-type Msh2 allele in tumor sites from mouse 36. In the single mouse in which the wild-type allele was retained at all four sites examined (left), a G to T transversion (asterisk) in exon 13 of the Msh2 gene was detected by sequencing after reverse transcription polymerase chain reaction analysis of the entire Msh2 coding sequence (right).
at University of Liege -Medical Library on November 3, 2010 jnci.oxfordjournals.org Downloaded from the HNPCC syndrome, one of the most common genetic predispositions to cancer in humans. However, unlike humans who carry a heterozygous mutation in a DNA mismatch repair gene, Msh2 ϩ/Ϫ mice do not spontaneously develop neoplasms with MSI. HNPCC is relatively prevalent, affecting 2%-5% of patients diagnosed with colorectal cancer (49) . Given that the lifetime risk of colorectal cancer is approximately 6% in the United States (50), we estimate that HNPCC may affect approximately one of 300-800 individuals in the general population. Moreover, because the evaluated incidence of HNPCC relies on the early age at cancer diagnosis and family history of cancer, it is likely to be underestimated because the penetrance of the syndrome may be largely incomplete and HNPCC may also be characterized by the emergence of late-onset tumors in some patients (51) . Finally, lymphomas that developed in azathioprine-treated Msh2 WT mice did not display MSI, whereas we previously detected MSI in a minority (8%) of lymphomas that developed in a large cohort (n = 111) of non-HNPCC patients treated with azathioprine and/or other immunosuppressants (21) . Together, the above observations indicate that azathioprine and, more broadly, the thiopurines constitute only a minor risk factor for the development of tumors with MSI in the general population. However, for individuals who carry mutations in DNA mismatch repair genes, exposure to azathioprine may be an important risk factor for the development of tumors with MSI. Our results could thus have important implications for the use of azathioprine in heterozygous carriers of DNA mismatch repair gene defects. On the basis of our findings, we recommend that more effort should be directed toward identifying possible cases of HNPCC among patients who are frequently prescribed thiopurines, such as transplant patients and patients suffering from inflammatory diseases. In addition, systematic screening for mutations in DNA mismatch repair genes in azathioprine-treated patients who subsequently developed DNA mismatch repair-deficient neoplasms could unmask previously unrecognized cases of HNPCC. Because earlier results by our group showed that MSI-associated lymphoproliferative disorders in transplant patients were usually late onset (22) , this possibility should be considered, especially when the tumor is diagnosed long after the immunosuppressive therapy. Consequently, we recommend systematic screening for MSI in lymphomas and other neoplasms that arise in patients treated with thiopurine drugs. This screening could be particularly important because tumors with MSI usually have a different prognosis and sensitivity to chemotherapeutic agents compared with tumors that lack MSI, as has been shown for colorectal carcinomas (52) .
To date, the mechanisms through which iatrogenic neoplasms arise in patients who are treated with different drugs in various clinical contexts are largely unknown. Here we show that mouse models can be highly relevant for the investigation of this issue because they can allow the identification of a known cancer pathway in relation to the prescription of a specific drug. Following on from these findings, we recommend that similar studies be carried out to determine whether other cancer-related genes play a role in the development of secondary neoplasms in response to other therapeutic agents. This study has provided further insight into the mechanisms that underlie azathioprine-induced carcinogenesis, including the ability of this drug to induce MSI-driven malignancy in Msh2 ϩ/Ϫ mice. The limitation of this study is that we did not investigate if such observations are specific for thiopurines or whether they could be extended to other frequently prescribed immunosuppressants whose actions are independent of DNA mismatch repair. It is generally considered that MSI tumors are tightly controlled by the host's immune system. Indeed, tumors that display MSI are characterized by a high level of lymphocytic infiltration due to their highly immunogenic nature (53) , and it has been shown that aberrant neoantigenic peptides resulting from genes carrying frameshift mutations may elicit an immune response against tumor cells displaying MSI, which could then limit their proliferation (54, 55) . Further studies analogous to this study involving other frequently prescribed immunosuppressants are required to determine whether a reduction in host immunosurveillance, by itself, plays a role in MSI-driven oncogenesis.
